Sveriges mest populära poddar

Season 1, Episode 24

18 min•11 juni 2020

In this week’s episode we’ll review results of a trial of venetoclax plus low-dose cytarabine in untreated patients with acute myeloid leukemia who are ineligible for intensive chemotherapy, learn how HRI-regulated transcription factor ATF4 activates BCL11A transcription to silence fetal hemoglobin expression, and assess new data demonstrating that aromatase is a novel neosubstrate of cereblon responsible for thrombocytopenia caused by immunomodulatory drugs.

Fler avsnitt av Blood Podcast

Cost-Effectiveness of Current SCD Treatments and Potential Therapeutic Targets for Fetal Hemoglobinopathies

13 aug.•33 min

HLH-like toxicities after CAR-T and Structure-Function Relationships of FNAIT

6 aug.•17 min

FLT3-ITD microclones in AML and Results from the RESET-PV trial

30 juli•14 min

Initial CHORUS data on HHT and ASH HematOmics Program

23 juli•26 min

IV Iron during Acute Infection and Revisiting iTTP Refractoriness

16 juli•17 min

A Pediatric ITP Risk Model and Targeting CD2 with CAR T-cell therapies

9 juli•18 min

IV Iron Risks and Low-Dose AML Gains

2 juli•25 min

Orca-T for GVHD–free survival and Understanding VEXAS anemia

25 juni•23 min

Treating AML, Before and After Relapse

18 juni•16 min

Future Directions in Relapsed and Refractory Large B-cell Lymphoma

11 juni•25 min

Blood Podcast med American Society of Hematology finns tillgänglig på flera plattformar. Informationen på denna sida kommer från offentliga podd-flöden.